FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							. ,				' '							
1. Name and Address of Reporting Person* CORRIGAN MARK					2. I: W	2. Issuer Name and Ticker or Trading Symbol Wave Life Sciences Ltd. [WVE]								eck all appli	ionship of Reporting Pers all applicable) Director			uer vner
(Last)	(F	irst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 08/12/2024								Office	Officer (give title below)		Other (s below)	·
C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE.					4. li	If Amendment, Date of Original Filed (Month/Day/Year)							Lin	Individual or Joint/Group Filing (Check Applicable ne) Form filed by One Reporting Person				
(Street) CAMBRIDGE MA 02138													Form to Person		e than	One Repor	ting	
(City) (State) (Zip)				- Ru	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to													
		Tah	lo I. No	n Dori	vativ						ns of Rule 1				4			
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				saction	ction 2A. Deemed Execution Date,			3. 4. Securit Transaction Code (Instr. 5)			ies Acquire Of (D) (Ins	ed (A) or	5. Amou Securiti Benefic	unt of es ially Following	Form (D) o	r Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) o (D)	r Price	Transac (Instr. 3	tion(s)			
Ordinary Shares 08/12/				2/202	/2024		A		32,230	(1) A	\$0.0	0 32	.,230		D			
		1	Table II -								osed of, onvertil			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	Date,	4. Transa Code (8)		ı of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	s Illy	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amount or Number of Shares					
Share Option (right to	\$5.37	08/12/2024			A		64,460		(2)	1	08/12/2029	Ordinary Shares	64,460	\$0.00	64,46	0	D	

Explanation of Responses:

- 1. The reporting person was granted this restricted share unit award (RSU) pursuant to the 2024 Non-Employee Director Compensation Policy. The RSU vests as to 50% on each of (i) the earlier of the Company's 2025 annual general meeting or August 12, 2025; and (ii) the earlier of the Company's 2026 annual general meeting or August 12, 2026.
- 2. The reporting person was granted this option pursuant to the 2024 Non-Employee Director Compensation Policy. The option vests as to 12.5% on a quarterly basis beginning August 12, 2024, through the two-year period following the grant date.

/s/ Mark Corrigan

08/14/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.